Definium Therapeutics, Inc.
DFTX
Peringkat dalam Saham
#3601
Definium Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm... Definium Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to developing innovative therapeutic solutions for various brain health and neurological disorders. Its pipeline features key experimental drug candidates like MM120, which is currently undergoing Phase 3 clinical trials for generalized anxiety disorder (GAD) and attention deficit hyperactivity disorder (ADHD). Another significant compound, MM402 – an R-enantiomer of 3,4-methylenedioxymethamphetamine – is in Phase 1 trials, targeting the fundamental symptoms of autism spectrum disorder. The company maintains its headquarters in New York, New York.
Harga Saham
$35.32
Kapitalisasi Pasar
$4.75B
Perubahan (1 hari)
7.12%
Perubahan (1 tahun)
222.95%
Negara
US
Perdagangan Definium Therapeutics, Inc. (DFTX)
Kategori
Healthcare
Riwayat hasil dividen untuk Definium Therapeutics, Inc. (DFTX)
Hasil dividen (TTM) dari Definium Therapeutics, Inc. (simbol saham: DFTX) per 2026: 0
Rata-rata hasil dividen selama 5 tahun terakhir: 0.00%
Rata-rata hasil dividen selama 5 tahun terakhir: 0.00%
Riwayat hasil dividen untuk Definium Therapeutics, Inc. (DFTX) dari 2026 hingga 2026
Hasil dividen pada akhir setiap tahun (TTM)
| Tahun | Hasil Dividen | Mengubah |
|---|---|---|
| Tidak cukup data untuk tanggal yang disediakan. | ||
Hasil dividen (TTM) untuk perusahaan serupa atau pesaing
| Perusahaan | Hasil Dividen | Negara |
|---|---|---|
| 0.00% |
US
|
|
| 0.00% |
US
|
|
| 2.17% |
AU
|
|
| 0.00% |
CH
|
|
| 0.00% |
NL
|
